Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: Long-term results of a placebo-control led randomised study
Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: Long-term results of a placebo-control led randomised study
复制标题
DOI：
10.1016/j.radonc.2008.02.007
复制
发表时间：
2008-06-01
影响因子：
5.7
通讯作者：
Shibamoto, Yuta
中科院分区：
文献类型：
--
作者：
Karasawa, Katsuyuki;Sunamura, Makoto;Shibamoto, Yuta
新的乏氧细胞放射增敏剂多拉硝唑用于术中放射治疗时不能切除的胰腺癌。短期生存率没有什么不同。然而，在3年生存率方面观察到差异（多拉硝唑组与安慰剂组; 23%与0%，p = 0.0192）。这种增敏剂可能有效地提高胰腺癌的长期生存率。(C)2008爱思唯尔爱尔兰有限公司保留所有权利。
Novel hypoxic cell radiosensitiser doranidazole was tested for unresectable pancreatic cancer administered at intraoperative radiotherapy. Short-term survival was not different. However, difference has been observed concerning 3-year survival (doranidazole group vs. placebo; 23% vs. 0%, p = 0.0192). This sensitiser might be effective in improving long-term survival for pancreatic cancer. (C) 2008 Elsevier Ireland Ltd. All rights reserved.